𝔖 Bobbio Scriptorium

✦ LIBER ✦

A computer programme to calculate for the individual the expected improvement in survival chance from adjuvant therapies

✍ Scribed by R. Blamey; Mitchell; G. Wishart; R. Macmillan; P. Pharoah

Book ID: 118624659
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 104 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80380-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A computer programme to calculate for th

A computer programme to calculate for the individual the expected improvement in survival chance from adjuvant therapies

✍ R Blamey; D Macmillan; G Wishart; D Morgan; M Mitchell 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 152 KB

O-32. A computer programme to calculate

O-32. A computer programme to calculate for the individual: the expected improvement in survival chance from adjuvant therapies

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 196 KB

182 Bicalutamide (‘Casodex’) 150 mg as a

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

✍ D. McLeod; P. Iversen; W. See; M. Wirth; K. Carroll; C. Morris; T. Morris 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB